Retrophin (RTRX) PT Raised to $46 at BMO as Details Strengthen DUET Data

November 21, 2016 9:35 AM EST
Get Alerts RTRX Hot Sheet
Price: $19.53 +1.67%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade RTRX Now!
Join SI Premium – FREE

Get the Pulse of the Market with's Pulse Picks. Get your Free Trial here.

BMO Capital analyst Do Kim reiterated an Outperform rating and raised his price target on Retrophin (NASDAQ: RTRX) to $46.00 (from $40.00) following positive updated DUET data at the ASN meeting.

Kim commented, "Our probability of success for Sparsentan increases to 55% from 45%, as we believe the results strengthen Retrophin's case for accelerated filing and launch in 2017. We believe the FDA will consider a dose titration for approval given an apparent dose-response in efficacy and tolerability (hypotension), with manageable edema rates. FDA acceptance of the proteinuria endpoint remains a risk, but we see growing evidence for proteinuria as a surrogate to kidney survival."

For an analyst ratings summary and ratings history on Retrophin click here. For more ratings news on Retrophin click here.

Shares of Retrophin closed at $20.08 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, FDA

Related Entities

BMO Capital

Add Your Comment